Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
J&J's BCMA/CD3 bispecific nabs a conditional EMA nod, jumping in front of FDA
3 years ago
VistaGen faces another fail as anxiety drug flops a PhIII study — shares crater
3 years ago
'Like a bulletproof vest': Cancer cells make their own kind of collagen. Can piercing through make treatments better?
3 years ago
Discovery
Small UK biotech touts long-term data for hemophilia B gene therapy as it attempts a comeback
3 years ago
Cell/Gene Tx
Roche trims out some pipeline failures while flagging a PhIII flop for Tecentriq
3 years ago
Pfizer to make major investment in vaccine R&D and manufacturing site in New York
3 years ago
Manufacturing
X4 slashes pipeline, lays off staff just three weeks after netting a $55M PIPE
3 years ago
People
John McHutchison throws in the towel on HBV drug, triggering layoffs as Assembly shifts to next-gen approaches
3 years ago
People
Microcap biotech's shares crater on a PhIII failure for heavy drinking drug
3 years ago
Without voluntary withdrawals, ODAC to review two more dangling accelerated approvals
3 years ago
FDA+
Scoop: AbbVie terminates early-stage study of I-Mab's antibody, another clinical setback in CD47 field
3 years ago
China
Updated: Small cannabinoid biotech says its CMO was hit with cyberattack, resulting in clinical trial delays
3 years ago
Keytruda hit with second PhIII setback this year as Merck's blockbuster flops certain head and neck trial
3 years ago
Bristol Myers vets tie up another all-stock deal, lining up clinical-stage oncology pipeline
3 years ago
Deals
Gene therapy for ovarian cancer fails PhIII study — sinking biotech's shares
3 years ago
Cell/Gene Tx
MDMA psychotherapy trial put on pause after Health Canada inspection
3 years ago
FDA+
Amgen, GSK, Regenxbio and others urge SCOTUS to review 'damaging' decision on biomedical patents
3 years ago
Law
As the pandemic high wanes, Inovio chops headcount again while chasing Covid win
3 years ago
People
Lynparza fails a PhIII test in colorectal cancer, cutting off big R&D avenue for Merck and AstraZeneca
3 years ago
Pharma
Editas hires top Sanofi scientist for CMO as C-suite shuffle continues
3 years ago
Sesen Bio pauses bladder cancer drug work, offloads eye disease antibodies to Roche
3 years ago
Eliem delays a depression trial, indefinitely postpones another after blaming CMC issues for low drug exposure
3 years ago
Kyowa Kirin pulls the plug on drug development for successor to Parkinson's drug Nourianz
3 years ago
As Big Pharma loses interest in new antibiotics, infections are only growing stronger
3 years ago
First page
Previous page
127
128
129
130
131
132
133
Next page
Last page